dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
Company profile
Ticker
DBVT
Exchange
Website
CEO
Daniel Tasse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
DBV Technologies Inc. • DBV Technologies Australia PTY Ltd. • DBV Pharma S.A.S. ...
DBVT stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
8 Apr 24
8-K
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
S-8
Registration of securities for employees
20 Nov 23
8-K
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
9 Nov 23
8-K/A
Departure of Directors or Certain Officers
6 Nov 23
8-K/A
Departure of Directors or Certain Officers
2 Nov 23
8-K
Termination of a Material Definitive Agreement
31 Oct 23
Transcripts
DBVT
Earnings call transcript
2023 Q3
31 Oct 23
DBVT
Earnings call transcript
2023 Q2
31 Jul 23
DBVT
Earnings call transcript
2022 Q4
2 Mar 23
DBVT
Earnings call transcript
2022 Q3
3 Nov 22
DBVT
Earnings call transcript
2022 Q1
2 May 22
DBVT
Earnings call transcript
2022 Q1
2 May 22
DBVT
Earnings call transcript
2021 Q4
4 Mar 22
DBVT
Earnings call transcript
2021 Q4
3 Mar 22
DBVT
Earnings call transcript
2021 Q3
26 Oct 21
DBVT
Earnings call transcript
2021 Q2
2 Aug 21
Latest ownership filings
4
Daniel Tasse
11 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
4
Adora Ndu
8 Feb 24
4
Pharis Mohideen
19 Dec 23
4
Virginie Boucinha
22 Nov 23
4
Daniel Tasse
22 Nov 23
4
Pharis Mohideen
22 Nov 23
3
Virginie Boucinha
7 Nov 23
4
TIMOTHY E MORRIS
28 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 149.14 mm | 149.14 mm | 149.14 mm | 149.14 mm | 149.14 mm | 149.14 mm |
Cash burn (monthly) | 8.28 mm | 5.29 mm | 6.09 mm | 8.65 mm | 6.52 mm | 7.49 mm |
Cash used (since last report) | 54.89 mm | 35.12 mm | 40.39 mm | 57.35 mm | 43.27 mm | 49.66 mm |
Cash remaining | 94.25 mm | 114.02 mm | 108.74 mm | 91.78 mm | 105.86 mm | 99.47 mm |
Runway (months of cash) | 11.4 | 21.5 | 17.9 | 10.6 | 16.2 | 13.3 |
Institutional ownership, Q2 2023
32.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 7 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 84.60 bn |
Total shares | 62.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 14.61 mm | $27.77 bn |
Braidwell | 12.11 mm | $23.00 bn |
Venrock Healthcare Capital Partners II | 9.40 mm | $0.00 |
Bpifrance Participations | 7.15 mm | $16.59 mm |
Fairmount Funds Management | 7.06 mm | $13.42 bn |
Point72 Asset Management | 3.11 mm | $5.91 bn |
Vivo Capital | 2.71 mm | $5.15 bn |
Boxer Capital | 1.45 mm | $2.76 mm |
Logos Global Management | 1.20 mm | $2.28 bn |
AMP Ameriprise Financial | 1.18 mm | $2.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Tasse Daniel | Ordinary Shares | Buy | Acquire P | No | No | 0.83 | 17,094 | 14.19 k | 17,094 |
6 Feb 24 | Adora Ndu | Ordinary Shares | Buy | Acquire P | No | No | 0.89 | 1,825 | 1.62 k | 1,825 |
22 Nov 23 | Pharis Mohideen | Ordinary Shares | Sell | Dispose S | No | No | 1.74 | 2,245 | 3.91 k | 82,194 |
20 Nov 23 | Pharis Mohideen | Ordinary Shares | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 84,439 |
20 Nov 23 | Pharis Mohideen | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 2.19 | 215,000 | 470.85 k | 215,000 |
20 Nov 23 | Tasse Daniel | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 2.19 | 806,672 | 1.77 mm | 806,672 |
News
DBV Technologies Q4 2023 GAAP EPS $(0.060), Sales $8.875M Beat $412.000K Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
A Preview Of DBV Technologies's Earnings
6 Mar 24
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $10 Price Target
21 Feb 24
DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying
9 Feb 24
Press releases
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
4 Apr 24
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
8 Mar 24
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
7 Mar 24
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
4 Mar 24
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
20 Feb 24